Cumberland Pharmaceuticals (CPIX, Financial) experienced significant stock movement with a 5.40% surge. The stock is currently priced at $1.17 per share, with a trading volume of 31,996 shares and a turnover rate of 0.23%. The stock's amplitude reached 7.21%.
Recent financial reports reveal that Cumberland Pharmaceuticals reported a revenue of $9.09 million, a net loss of $1.54 million, and an earnings per share (EPS) of -$0.11. The company's gross profit stood at $6.65 million, with a price-to-earnings (P/E) ratio of -1.51. Currently, no institutional ratings are available for buy, hold, or sell recommendations.
Within the pharmaceutical industry, the overall increase was 0.58%. Notable performers include Im Cannabis Corp., Medicus Pharma Ltd., and Procaps Group S.A. C/Wts 29/09/2026 (To Pur Com), which saw significant gains. Active stocks with high turnover rates include Im Cannabis Corp. at 95.28%, Painreform Ltd. at 24.81%, and Sunshine Biopharma Inc. at 17.15%. Stocks with large amplitude in the sector include Procaps Group S.A. C/Wts 29/09/2026 (To Pur Com) at 54.75%, Im Cannabis Corp. at 39.34%, and Biofrontera Inc C/Wts 27/10/2026 (To Pur Com) at 36.30%.
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products. The company targets markets such as hospital acute care, gastroenterology, rheumatology, and oncology. It promotes its FDA-approved products through its hospital, field, and oncology sales divisions in the U.S., and is building an international partner network for product registration and distribution. Its product portfolio includes brands like Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol, and Vibativ.
